Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
about
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disordersDegeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's DiseaseParkinson's disease, insulin resistance and novel agents of neuroprotectionGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideGIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signalingNetwork-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.Insulin resistance impairs nigrostriatal dopamine functionRole for neuronal insulin resistance in neurodegenerative diseasesProspective cohort study of type 2 diabetes and the risk of Parkinson's diseaseInsulin, leptin, and food reward: update 2008.Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's diseaseLeptin neuroprotection in the CNS: mechanisms and therapeutic potentialsAgonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's DiseaseInsulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets.Insulin receptor signaling in the development of neuronal structure and function.Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies.Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy.Mechanisms of action of brain insulin against neurodegenerative diseases.Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.Commonality between diabetes and Alzheimer's disease and a new strategy for the therapyInsulin and the Brain: A Sweet Relationship With Intensive Care.Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.Molecular changes in the postmortem parkinsonian brain.The best medicine? The influence of physical activity and inactivity on Parkinson's disease.Increased levels of insulin and insulin-like growth factor-1 hybrid receptors and decreased glycosylation of the insulin receptor alpha- and beta-subunits in scrapie-infected neuroblastoma N2a cells.Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer's disease rat model.Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
P2860
Q24562763-FA968238-AA6F-40F8-A315-56C3BB4BF2E3Q26750370-4A1FD15F-3472-423D-AD1D-75E1DDF1821AQ26853311-696A5D91-D5B8-45AE-B119-2E64341D8394Q28067465-3E27792F-7CE7-48EC-BBD4-E7A2C9D432C4Q28081671-2C09D75D-927A-423D-A985-6A91CD16042FQ28593816-D4F5D72D-E045-44D4-9147-1A81DBEF4134Q35129144-666D89FB-0F32-4B91-8F00-DCC517F275A0Q35202338-6EADA12C-40EC-48E6-8F7B-593ECA7DB92DQ36853917-E02ACA67-D3DB-4566-AAB2-2FD9667CE227Q36906241-B6ECC450-207E-49EA-892A-8923AEEC8A3FQ37086372-5FBC2619-3DD3-4C6C-8CAE-0609503834E8Q37151436-4ECE8FB0-74D3-4E31-A55C-F7836A9C6DCCQ37157927-CBE23F7E-470C-4DF7-A46E-41DB43E323E1Q37211800-FE783324-693F-4D34-B303-F08AF9E4FD7FQ37689883-E5677584-FC3F-4657-A22D-A83A84789189Q37709539-CEC20513-00E9-48E1-8B5F-A252A583FD88Q37962621-97632F0D-24C2-4497-8FA9-AE7A281CEE6DQ38039489-3181FEEB-151F-4204-A235-EF212D8CB53FQ38075505-D9C89A1E-ED54-4F45-A9E1-B5C33D0D9590Q38086474-007CC64F-6DBD-49FC-8A1D-C8F55ADF6A8DQ38176522-2292289F-8702-4881-9ABE-F74622BE4739Q38197368-F2CC285A-9F6E-4029-B9E3-96AD0206BBF1Q38253931-385B9826-FEF6-47E0-A70F-C992863ECA28Q38546134-F4E14088-771D-4065-B7FF-48D46637594EQ38668948-5F660093-0DD0-42F5-A38B-EB9795816924Q38887346-226969A6-ACE2-4DDF-9318-A6B845610AA6Q38914196-AEEA6E81-C778-4806-BEB9-04670D7D486AQ40577873-47FDEFC4-7543-447F-BF87-BA096B8BEFC4Q47835103-741D608C-A35B-43C4-9474-64F6FCD79148Q48297749-B164C3B9-5736-4FF3-B45E-F78DAE8E3418Q48552944-4B51EACC-A745-4449-A86B-AABD6EFC5290Q58737028-0C23A456-890C-4AE9-9516-736D4C1695EA
P2860
Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Loss of insulin receptor immun ...... eurons in Parkinson's disease.
@en
Loss of insulin receptor immun ...... eurons in Parkinson's disease.
@nl
type
label
Loss of insulin receptor immun ...... eurons in Parkinson's disease.
@en
Loss of insulin receptor immun ...... eurons in Parkinson's disease.
@nl
prefLabel
Loss of insulin receptor immun ...... eurons in Parkinson's disease.
@en
Loss of insulin receptor immun ...... eurons in Parkinson's disease.
@nl
P2093
P921
P356
P1476
Loss of insulin receptor immun ...... eurons in Parkinson's disease.
@en
P2093
P2888
P304
P356
10.1007/BF00313602
P50
P577
1994-01-01T00:00:00Z